Eliem Therapeutics
Eliem Therapeutics is a biopharmaceutical company focused on developing therapies for neuronal excitability disorders, with key projects including ETX-155 for major depressive disorder and focal onset seizures.
Services
Eliem Therapeutics focuses on developing novel therapies for disorders related to neuronal excitability. The company is engaged in both clinical and preclinical development, targeting central and peripheral nervous system conditions. The aim is to address unmet needs in areas such as psychiatry, epilepsy, and chronic pain.
Products
Eliem Therapeutics' product pipeline includes ETX-155, which is being developed to treat major depressive disorder and focal onset seizures. ETX-155 is part of the company's extensive clinical trials program, where mechanisms of action are clinically validated. The company discontinued the ETX-810 program after it did not meet primary endpoints in clinical trials.
History
Eliem Therapeutics has made significant financial and strategic moves to support its development efforts. The company raised $60 million in Series B financing to advance its clinical programs and completed an IPO, raising $92 million in gross proceeds. In addition to these financial milestones, the company announced plans to explore strategic alternatives to maximize shareholder value.
Clinical Trials
Eliem Therapeutics is focused on advancing its clinical programs. The company plans to initiate Phase 2a trials for ETX-155 in major depressive disorder. Despite the setback with the ETX-810 program, which did not meet primary endpoints in clinical trials, Eliem continues to push forward with its innovative approaches to treating neuronal excitability disorders.